Clinical trials: Unresectable Hepatocellular Carcinoma
Liver Cancer
Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00875615
- Testing
- Carboplatin, Cisplatin, Sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Miami
Liver Cancer
Gene Therapy in Treating Patients With Cancer of The Liver
Phase I trial to study the effectiveness of gene therapy with the p53 gene in treating patients who have cancer of the liver that cannot be surgically removed.
- Trial name
- NCT00003147
- Testing
- Ad5CMV-p53 gene
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
M-TACE Treatment for Unresectable Hepatocellular Carcinoma
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).
- Trial name
- NCT05875558
- Testing
- M-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres
The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective…
- Trial name
- NCT04903548
- Testing
- SIRT with Y-90 resin microspheres
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Methodist Health System
Hepatocellular Carcinoma Non-resectable, HCC
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
- Trial name
- IMMUWIN (NCT04522544)
- Testing
- Tremelimumab, Durvalumab, Y-90 SIRT
- Where
- 11 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of SBRT combined with cardonilizumab and lenvastinib in the treatment of unresectable hepatocellular carcinoma with portal vein tumor…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors
- Trial name
- NCT06040177
- Testing
- Cadonilimab, Stereotactic radiotherapy, Renvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Carcinoma, Hepatocellular
Dynamic Contrast Enhanced HCC SABR Liver Study
The high dose per fraction (>10Gy/fraction) used in Stereotactic Ablative Body Radiotherapy (SABR) has been shown to be more effective at local tumor control than treatments employing more conventional dose fractions.
- Trial name
- NCT02847767
- Testing
- Perfusion Imaging
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Liver Cancer
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or…
- Trial name
- NCT00257426
- Testing
- octreotide acetate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
A randomized trial showed that sorafenib plus hepatic artery infusion of 85mg/m² oxaliplatin, leucovorin and fluorouracil is more effective than sorafenib in advanced hepatocellular carcinoma.
- Trial name
- NCT04687163
- Testing
- HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
Unlike the Asian and western regions, The vast majority of the Egyptian/Arabic Hepatocellular Carcinoma (HCC) patients are hepatitis C virus (HCV) associated.
- Trial name
- NCT01539018
- Testing
- Sorafenib, sorafenib plus tegafur-uracil
- Where
- 5 sites in Egypt
- Volunteers
- 77 people
- Sponsor
- Egyptian Society of Liver Cancer
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.
- Trial name
- NCT06034977
- Testing
- ADI-PEG20
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma Non-resectable
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03533920
- Testing
- UNI-DEB
- Where
- 8 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma (HCC)
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
The goal of this clinical trial is to learn if lenvatinib or regorafenib can help treat people with advanced liver cancer (hepatocellular carcinoma, HCC) that cannot be removed with surgery after first treatment with…
- Trial name
- REVIVE (NCT07495579)
- Testing
- Lenvatinib, regorafenib
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
- Trial name
- SERENADE-T (NCT03283956)
- Testing
- Patient records
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Hepatocellular Carcinoma Non-resectable
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
The vast majority of primary liver cancer (90%) is hepatocellular carcinoma (HCC), and the majority of HCC patients have been locally advanced or metastatic disease when they are diagnosed in clinics.
- Trial name
- PLTHCC (NCT04273100)
- Testing
- PD-1 mAb combined with TACE and lenvatinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital